← Leaderboards
Joshua M Hare
Johns Hopkins University
$39,853,111
Attributed
$46,200,179
Total exposure
22
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$48,526,580 · 23
By mechanism
R01$23,975,792 · 8
U54$6,534,022 · 3
UM1$4,338,477 · 1
R44$4,240,853 · 1
UH3$3,521,212 · 1
P20$1,528,666 · 1
Top collaborators
- Anthony Andrew Oliva6 shared
- Sunjay Kaushal3 shared
- Sean X Leng3 shared
- Ivonne H Schulman3 shared
- Stuart Berger2 shared
- Aisha Khan2 shared
- Kiona Allen1 shared
- Michael L. Terrin1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Gregory G Germino$9,875,396
- David Alan Kass$45,555,857
- Steven R Houser$38,276,246
- Leslie Tung$12,122,938
- Richard Lange$2,493,077
Others in their field
Top investigators on “Cardiac”
- Judith S Hochman · New York University School Of Medicine$110,228,771
- Anne Christine Gelijns · Icahn School Of Medicine At Mount Sinai$69,868,084
- Rose A Gubitosi-Klug · Case Western Reserve University$61,225,818
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,141,827
- Joseph C Wu · Stanford University$53,027,789
- Pamela Susan Douglas · Duke University$51,506,531
Research focus
CardiacHeartHeart FailureProgramsStem CellsInsightCellsClinical TrialsMyocardial InfarctionMesenchymal Stem CellsBaseStem Cell TherapySafetyCell TherapyPre-ClinicalFamily SuidaeMediatingMyocardial IschemiaInjection Of Therapeutic AgentMyocardialCardiac MyocytesCardiovascular SystemMagnetic Resonance ImagingDesign
Grant awards (90)
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial$408,351
UH3 · FY2024 · HL
Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular Disease$213,492
U01 · FY2024 · HL · contact PI
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial$898,221
UH3 · FY2023 · HL
Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular Disease$288,744
U01 · FY2023 · HL · contact PI
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial$1,036,319
UH3 · FY2022 · HL
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial$1,178,321
UH3 · FY2021 · HL
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty$1,974,282
R44 · FY2020 · AG
Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities Cell manufacturing and process development services for PCT0031-02: GMP Production of iPSC Line and Scale-up of Cardiac$1,017,177
N01 · FY2020 · HL · contact PI
Cardioprotective Effect of Growth Hormone Releasing Hormone$669,004
R01 · FY2020 · HL · contact PI
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial$657,935
UG3 · FY2020 · HL
Mesenchymal stem cell therapy for endothelial dysfunction in diabetes$538,561
R01 · FY2020 · HL · contact PI
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$435,997
R42 · FY2020 · AG · contact PI
Nitric Oxide and sex differences in cardiac repair$383,750
R01 · FY2020 · HL · contact PI
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty$1,983,531
R44 · FY2019 · AG
Mesenchymal stem cell therapy for endothelial dysfunction in diabetes$687,355
R01 · FY2019 · HL · contact PI
Cardioprotective Effect of Growth Hormone Releasing Hormone$669,004
R01 · FY2019 · HL · contact PI
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$465,489
R42 · FY2019 · AG · contact PI
Nitric Oxide and sex differences in cardiac repair$390,167
R01 · FY2019 · HL · contact PI
Mesenchymal stem cell therapy for endothelial dysfunction in diabetes$687,355
R01 · FY2018 · HL
Cardioprotective Effect of Growth Hormone Releasing Hormone$669,004
R01 · FY2018 · HL · contact PI
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy$587,071
UM1 · FY2018 · HL · contact PI
Nitric Oxide and sex differences in cardiac repair$392,763
R01 · FY2018 · HL · contact PI
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty$283,040
R44 · FY2018 · AG
Mesenchymal stem cell therapy for endothelial dysfunction in diabetes$677,730
R01 · FY2017 · HL
Cardioprotective Effect of Growth Hormone Releasing Hormone$669,004
R01 · FY2017 · HL · contact PI
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy$570,141
UM1 · FY2017 · HL · contact PI
Nitric Oxide and sex differences in cardiac repair$406,138
R01 · FY2017 · HL · contact PI
IGF::OT::IGF - PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES$381,289
N01 · FY2017 · HL · contact PI
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$150,000
R42 · FY2017 · AG · contact PI
Mesenchymal stem cell therapy for endothelial dysfunction in diabetes$649,405
R01 · FY2016 · HL
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy$576,152
UM1 · FY2016 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$382,500
R01 · FY2016 · HL · contact PI
Cardioprotective Effect of Growth Hormone Releasing Hormone$631,836
R01 · FY2015 · HL · contact PI
Stem Cells for Dilated Cardiomyopathy$604,129
R01 · FY2015 · HL · contact PI
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy$574,293
UM1 · FY2015 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$376,762
R01 · FY2015 · HL · contact PI
Pathways to Cardiovascular Therapeutics$30,000
R13 · FY2015 · HL · contact PI
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy$664,596
UM1 · FY2014 · HL · contact PI
Cardioprotective Effect of Growth Hormone Releasing Hormone$648,397
R01 · FY2014 · HL · contact PI
Stem Cells for Dilated Cardiomyopathy$638,895
R01 · FY2014 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$374,850
R01 · FY2014 · HL · contact PI
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy$650,680
UM1 · FY2013 · HL · contact PI
Cardioprotective Effect of Growth Hormone Releasing Hormone$649,300
R01 · FY2013 · HL · contact PI
Stem Cells for Dilated Cardiomyopathy$620,241
R01 · FY2013 · HL · contact PI
Nitroso/redox balance in myocardial infarction$423,946
R01 · FY2013 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$364,140
R01 · FY2013 · HL · contact PI
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy$715,544
UM1 · FY2012 · HL · contact PI
Stem Cells for Dilated Cardiomyopathy$651,265
R01 · FY2012 · HL · contact PI
Cardioprotective Effect of Growth Hormone Releasing Hormone$625,461
R01 · FY2012 · HL · contact PI
Nitroso/redox balance in myocardial infarction$445,322
R01 · FY2012 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$382,500
R01 · FY2012 · HL · contact PI
Autologous Adult Myocardial Cardioblasts to Treat Ischemic Heart Failure$763,799
P20 · FY2011 · HL · contact PI
Cardioprotective Effect of Growth Hormone Releasing Hormone$644,337
R01 · FY2011 · HL · contact PI
Stem Cells for Dilated Cardiomyopathy$639,505
R01 · FY2011 · HL · contact PI
Nitroso/redox balance in myocardial infarction$445,322
R01 · FY2011 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$382,500
R01 · FY2011 · HL · contact PI
Autologous Adult Myocardial Cardioblasts to Treat Ischemic Heart Failure$764,867
P20 · FY2010 · HL · contact PI
Nitroso/redox balance in myocardial infarction$449,820
R01 · FY2010 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$382,500
R01 · FY2010 · HL · contact PI
Mesenchymal Stem Cell Cardiomyoplasty$644,367
U54 · FY2009 · HL · contact PI
Nitroso/redox balance in myocardial infarction$459,000
R01 · FY2009 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$382,500
R01 · FY2009 · HL · contact PI
Mesenchymal Stem Cell Cardiomyoplasty$574,264
U54 · FY2008 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$382,500
R01 · FY2008 · HL · contact PI
Oxidative Stress in Heart Failure: Mechanisms$326,412
R01 · FY2008 · HL · contact PI
Aging impairs stem-cell mediated myocardial repair$284,340
R01 · FY2008 · AG · contact PI
Mesenchymal Stem Cell Cardiomyoplasty$661,957
U54 · FY2007 · HL · contact PI
Cellular Cardiomyoplasty for Chronic Heart Failure$382,500
R01 · FY2007 · HL · contact PI
Oxidative Stress in Heart Failure: Mechanisms$326,412
R01 · FY2007 · HL · contact PI
Aging impairs stem-cell mediated myocardial repair$290,143
R01 · FY2007 · AG · contact PI
SAFETY OF MESENCHYMAL STEM CELLS$4,013
M01 · FY2007 · RR · contact PI
Mesenchymal Stem Cell Cardiomyoplasty$1,181,793
U54 · FY2006 · HL · contact PI
Oxidative Stress in Heart Failure: Mechanisms$359,322
R01 · FY2006 · HL · contact PI
Aging impairs stem-cell mediated myocardial repair$194,316
R01 · FY2006 · AG · contact PI
Aging impairs stem-cell mediated myocardial repair$125,000
R01 · FY2006 · AG · contact PI
SAFETY OF MESENCHYMAL STEM CELLS$7,672
M01 · FY2006 · RR · contact PI
Cellular Cardiomyoplasty for Acute and Chronic Ischemic$2,326,401
U54 · FY2005 · HL
Mesenchymal Stem Cell Cardiomyoplasty$975,618
U54 · FY2005 · HL
Oxidative Stress in Heart Failure: Mechanisms$366,844
R01 · FY2005 · HL
Aging impairs stem-cell mediated myocardial repair$327,000
R01 · FY2005 · AG
CORE A- ADMINISTRATIVE CORE$169,622
U54 · FY2005 · HL
Aging impairs stem-cell mediated myocardial repair$327,000
R01 · FY2004 · AG
Mesenchymal Stem Cells and Ventricular Remodeling$245,250
R21 · FY2004 · HL
OXIDATIVE STRESS IN HEART FAILURE: MECHANISMS$286,125
R01 · FY2003 · HL
Mesenchymal Stem Cells and Ventricular Remodeling$245,250
R21 · FY2003 · HL
OXIDATIVE STRESS IN HEART FAILURE: MECHANISMS$286,125
R01 · FY2002 · HL
Mesenchymal Stem Cells and Ventricular Remodeling$245,250
R21 · FY2002 · HL
OXIDATIVE STRESS IN HEART FAILURE: MECHANISMS$57,225
R01 · FY2002 · HL
OXIDATIVE STRESS IN HEART FAILURE: MECHANISMS$286,125
R01 · FY2001 · HL
OXIDATIVE STRESS IN HEART FAILURE: MECHANISMS$274,135
R01 · FY2000 · HL